Refractory Ovarian Carcinoma Recruiting Phase 2 Trials for Tremelimumab (DB11771)

IndicationStatusPhase
DBCOND0110942 (Refractory Ovarian Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03026062Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerTreatment